Vaxart, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 4, 2023 and accepted by EDGAR at May 4, 2023, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-01-01 to 2023-03-31 | $19.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$25.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $29.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$25.1m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.19 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$24.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $1.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2023-03-31 | $75.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $129.9m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $15.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $40.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $89.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-23-012560. Last ingested by Listed: Nov 5, 2026, 18:48 ET. Listed shows no prices and gives no investment advice.